Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PRGN-3005 |
Synonyms | |
Therapy Description |
PRGN-3005 are UltraCAR T-cells expressing a chimeric antigen receptor (CAR) targeting MUC16, IL-15, and a kill switch, which potentially inhibit tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 5590). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRGN-3005 | PRGN3005|PRGN 3005 | MUC16 Targeted Therapy 10 | PRGN-3005 are UltraCAR T-cells expressing a chimeric antigen receptor (CAR) targeting MUC16, IL-15, and a kill switch, which potentially inhibit tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 5590). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03907527 | Phase I | PRGN-3005 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |